Miragen, InVitro Deal Revised

InVitro International said Monday that it has revised its merger agreement with privately held Miragen Inc. of Irvine, so that InVitro shareholders will receive 10% of the common stock of the combined company after the deal is completed.

The agreement still must be approved by directors of both companies.

Miragen manufactures and markets biological testing products for human and animal identification in various clinical laboratory, hospital, animal and forensic applications. InVitro International develops, manufactures and sells non-animal toxicity testing products and services.